Patents Assigned to Cerevance, Inc.
  • Heterobicyclic amides as inhibitors of CD38
    Publication number: 20260224582
    Abstract: The present invention provides compounds of formula (I): 5 A 1 X Y N R 2 R 1 A 2 A 3 A 4 n Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, n, A1, A2, A3, A4, X and Y are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for 10 use in treating disorders associated with CD38 activity.
    Type: Application
    Filed: May 18, 2023
    Publication date: August 6, 2026
    Applicant: Cerevance, Inc.
    Inventors: Roland Burli, Kevin Doyle, Andrew Stott
  • N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors
    Publication number: 20250019369
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Het, X1, X2, L, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for use in treating disorders associated with CD38 activity.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 16, 2025
    Applicant: Cerevance, Inc.
    Inventors: Roland Burli, Kevin Doyle